Serum tartrate-resistant acid phosphatase 5b activity as a prognostic marker of survival in breast cancer with bone metastasis.

BMC Cancer 2010 Apr 23;10:158. Epub 2010 Apr 23.

Breast Cancer Research Group, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.

Background: Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) activity is a marker of osteoclast number and is elevated in breast cancer (BC) patients with extensive bone metastasis, which might in turn reflect the tumour burden. We tested the hypothesis that baseline serum TRACP 5b activity and its interval change are potential prognostic markers of survival in BC patients with bone metastasis.

Methods: We analyzed the data from previous prospective studies. A total of 100 patients with newly diagnosed bone metastasis were included. Cox proportional regression model was used to evaluate the correlation between the overall survival time (OS) and baseline serum TRACP 5b activity and its interval changes. The least significant change (LSC) of TRACP 5b was calculated from data obtained from 15 patients with early BC.

Results: Estrogen receptor status (Hazard Ratio (HR) = 0.397; p = 0.003) and visceral metastasis (HR = 0.492; p = 0.0045) were significantly correlated with OS. The OS was significantly shorter in those patients with higher baseline TRACP 5b activity based on a cut-off value to delineate the highest tertile (HR = 3.524; p < 0.0001). Further analysis demonstrated that among patients in the highest tertile, OS was significantly longer in those patients who had achieved a decrease of serum TRACP 5b activity greater than the LSC (38.59%) (p = 0.0015).

Conclusions: We found that TRACP 5b activity and its interval change after treatment bore a prognostic role in BC patients with bone metastasis and a high baseline serum TRACP 5b activity. Further prospective phase II study is necessary to confirm these results.

Download full-text PDF

Source
http://bmccancer.biomedcentral.com/articles/10.1186/1471-240
Publisher Site
http://dx.doi.org/10.1186/1471-2407-10-158DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873389PMC
April 2010
6 Reads

Publication Analysis

Top Keywords

tracp activity
28
serum tracp
16
bone metastasis
16
baseline serum
12
activity interval
12
patients
8
acid phosphatase
8
interval change
8
tracp
8
serum tartrate-resistant
8
patients bone
8
highest tertile
8
breast cancer
8
activity
8
tartrate-resistant acid
8
serum
6
metastasis
5
bone
5
bcresults estrogen
4
0397 0003
4

References

(Supplied by CrossRef)

M Brown et al.
Cancer 2008

JJ James et al.
Br J Cancer 2003

R Coleman et al.
Cancer Treat Rev 2008

RE Coleman et al.
Clin Cancer Res 2006

N Voorzanger-Rousselot et al.
Br J Cancer 2006

A Lipton et al.
Oncologist 2007

A Lipton et al.
Cancer 2008

YC Chung et al.
Cancer Epidemiol Biomarkers Prev 2006

JM Halleen et al.
J Bone Miner Res 2000

A Nenonen et al.
J Bone Miner Res 2005

CJ Chen et al.
J Pediatr Endocrinol Metab 2005

Similar Publications